SurgicEye will present its 3-D imaging and navigation device declipseSPECT at the 65th Annual Cancer Symposium of the Society of Surgical Oncology, March 21-24, 2012, at the Orlando World Center Marriott in Orlando, Florida.

SurgicEye has worldwide the first 3-D handheld soft tissue imaging solution that is capable of image guided tumor resection. Visit us at the SurgicEye - Dilon Diagnostics booth: #119, and use the opportunity to meet Dr. Joerg Traub CEO and co-founder of SugicEye GmbH to learn more about the application and technology behind the declipseSPECT. To schedule an appointment please contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

The declipseSPECT from SurgicEye is the world’s first FDA and CE certified product for intra-operative 3D imaging of Tc99m labeled structures using existing gamma probe technology. Without adding any additional hardware, the declipseSPECT goes further and provides localization and guided biopsy of sentinel lymph nodes in breast cancer and melanoma. declipseSPECT enables sentinel lymph node biopsy procedures for melanoma and in the breast to be more sensitive, more reliable and less invasive.

Ongoing clinical investigations in other tumor surgery domains promise a wide application domain and huge potential for quality assurance during surgical interventions.